Skip to main content
Top
Published in: Rheumatology International 5/2011

01-05-2011 | Short Communication

Long-term remission after successful pregnancy in autologous peripheral blood stem cell transplanted system lupus erythematosus patients

Authors: Jianbo Meng, Jinkai Wang, Wenjie Liang, Shan Qin, Chuntao Wu

Published in: Rheumatology International | Issue 5/2011

Login to get access

Abstract

Pregnancies in systemic lupus erythematosus (SLE) patients are high risk to both mother and fetus because of increased rates of complications. During the past years, we have treated many cases of SLE patients using autologous peripheral blood stem cell transplantation with good outcome after pregnancy. The rate of maternal hypertension and lupus nephritis was greatly reduced in autologous peripheral blood stem cell transplanted group (n = 11) when compared to non-transplant group (n = 39) (P < 0.05). In addition, the outcome of lupus flare activity of the mother after delivery is significantly better in transplanted group than that in non-transplanted group (P < 0.05). Here, we describe two typical cases of long duration (>6 years) of remission after successful pregnancy in refractory SLE patients post-autologous peripheral blood stem cell transplantation. Our report demonstrated that peripheral blood stem cell transplantation is safe and effective, thereby could be recommended as prior strategy in refractory SLE patients, especially for those women of child-bearing age who plan for pregnancy.
Literature
1.
go back to reference Clowse M, Jamison M, Myers E et al (2008) A national study of the complications of lupus pregnancy. Am J Obstet Gynecol 199:127.e1–127.e6CrossRef Clowse M, Jamison M, Myers E et al (2008) A national study of the complications of lupus pregnancy. Am J Obstet Gynecol 199:127.e1–127.e6CrossRef
2.
3.
go back to reference Wagner SJ, Craici I, Reed D et al (2009) Maternal and fetal outcomes in pregnant patients with active lupus nephritis. Lupus 18:342–347PubMedCrossRef Wagner SJ, Craici I, Reed D et al (2009) Maternal and fetal outcomes in pregnant patients with active lupus nephritis. Lupus 18:342–347PubMedCrossRef
4.
go back to reference Burt RK, Traynor AE (2003) Hematopoietic stem cell transplantation for systemic lupus erythematosus. Arthritis Res Ther 5:207–209PubMedCrossRef Burt RK, Traynor AE (2003) Hematopoietic stem cell transplantation for systemic lupus erythematosus. Arthritis Res Ther 5:207–209PubMedCrossRef
5.
go back to reference Marmont AM (1998) Stem cell transplantation for severe autoimmune diseases: progress and problems. Haematologica 83:733–743PubMed Marmont AM (1998) Stem cell transplantation for severe autoimmune diseases: progress and problems. Haematologica 83:733–743PubMed
6.
7.
go back to reference Molad Y, Borkowski T, Monselise A et al (2005) Maternal and fetal outcome of lupus pregnancy: a prospective study of 29 pregnancies. Lupus 14:145–151PubMedCrossRef Molad Y, Borkowski T, Monselise A et al (2005) Maternal and fetal outcome of lupus pregnancy: a prospective study of 29 pregnancies. Lupus 14:145–151PubMedCrossRef
8.
go back to reference Marmont AM, van Lint MT, Gualandi F et al (1997) Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration. Lupus 6:545–548PubMedCrossRef Marmont AM, van Lint MT, Gualandi F et al (1997) Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration. Lupus 6:545–548PubMedCrossRef
9.
go back to reference Burt RK, Traynor A, Ramsey-Goldman R (1997) Hematopoietic stem cell transplantation for systemic lupus erythematosus. N Engl J Med 337:1777–1778PubMedCrossRef Burt RK, Traynor A, Ramsey-Goldman R (1997) Hematopoietic stem cell transplantation for systemic lupus erythematosus. N Engl J Med 337:1777–1778PubMedCrossRef
10.
go back to reference Traynor AE, Schroeder J, Rosa RM et al (2000) Treatment of severe systemic lupus erythematosus with high-dose of chemotherapy and haemopoietic stem-cell transplantation: a phase I study. Lancet 356:701–707PubMedCrossRef Traynor AE, Schroeder J, Rosa RM et al (2000) Treatment of severe systemic lupus erythematosus with high-dose of chemotherapy and haemopoietic stem-cell transplantation: a phase I study. Lancet 356:701–707PubMedCrossRef
11.
go back to reference Traynor A, Burt RK (1999) Haematopoietic stem cell transplantation for active systemic lupus erythematosus. Rheumatology 8:767–772CrossRef Traynor A, Burt RK (1999) Haematopoietic stem cell transplantation for active systemic lupus erythematosus. Rheumatology 8:767–772CrossRef
12.
go back to reference Burt RK, Slavin S, Burns Wh et al (2002) Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? Blood 99:870–887CrossRef Burt RK, Slavin S, Burns Wh et al (2002) Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? Blood 99:870–887CrossRef
13.
go back to reference Traynor A, Barr WG, Rosa RM et al (2002) Hametopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arthritis Rheum 46:2917–2923PubMedCrossRef Traynor A, Barr WG, Rosa RM et al (2002) Hametopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arthritis Rheum 46:2917–2923PubMedCrossRef
14.
go back to reference Theophilopoulos AN (1995) The basis of autoimmunity: part II. Genetic predisposition. Immunol Today 16:150–159CrossRef Theophilopoulos AN (1995) The basis of autoimmunity: part II. Genetic predisposition. Immunol Today 16:150–159CrossRef
15.
go back to reference Marmont AM (1994) Immune ablation followed by a allogeneic or autologous bone marrow transplantation: a new treatment for severe autoimmune diseases? Stem Cells 12:125–135PubMedCrossRef Marmont AM (1994) Immune ablation followed by a allogeneic or autologous bone marrow transplantation: a new treatment for severe autoimmune diseases? Stem Cells 12:125–135PubMedCrossRef
16.
go back to reference Buyon JP, Petri MA, Kim MY et al (2005) The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trail. Ann Intern Med 142:953–962PubMed Buyon JP, Petri MA, Kim MY et al (2005) The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trail. Ann Intern Med 142:953–962PubMed
17.
go back to reference Pisoni CN, D’Cruz DP (2008) The safety of mycophenolate mofetil in pregnancy. Expert Opin Drug Saf 7:219–222PubMedCrossRef Pisoni CN, D’Cruz DP (2008) The safety of mycophenolate mofetil in pregnancy. Expert Opin Drug Saf 7:219–222PubMedCrossRef
18.
go back to reference Thompson A, Han VKM, Yang K (2002) Spatial and temporal patterns of expression of 11b-hydroxysteroid dehydrogenase types 1 and 2 messenger RNA and glucocorticoid receptor protein in the murine placenta and uterus during late pregnancy. Biol Reprod 67:1708–1718PubMedCrossRef Thompson A, Han VKM, Yang K (2002) Spatial and temporal patterns of expression of 11b-hydroxysteroid dehydrogenase types 1 and 2 messenger RNA and glucocorticoid receptor protein in the murine placenta and uterus during late pregnancy. Biol Reprod 67:1708–1718PubMedCrossRef
Metadata
Title
Long-term remission after successful pregnancy in autologous peripheral blood stem cell transplanted system lupus erythematosus patients
Authors
Jianbo Meng
Jinkai Wang
Wenjie Liang
Shan Qin
Chuntao Wu
Publication date
01-05-2011
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 5/2011
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-010-1588-x

Other articles of this Issue 5/2011

Rheumatology International 5/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.